Byrne Asset Management LLC Has $27,000 Stock Holdings in Lexaria Bioscience Corp. (NASDAQ:LEXX)

Byrne Asset Management LLC boosted its stake in shares of Lexaria Bioscience Corp. (NASDAQ:LEXX) by 132.1% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 13,000 shares of the company’s stock after buying an additional 7,400 shares during the period. Byrne Asset Management LLC owned approximately 0.07% of Lexaria Bioscience worth $27,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of LEXX. Geode Capital Management LLC boosted its position in Lexaria Bioscience by 31.0% during the 3rd quarter. Geode Capital Management LLC now owns 150,391 shares of the company’s stock worth $459,000 after acquiring an additional 35,608 shares during the last quarter. Renaissance Technologies LLC acquired a new position in Lexaria Bioscience during the second quarter worth $63,000. HighTower Advisors LLC bought a new position in Lexaria Bioscience in the third quarter valued at $40,000. Finally, XTX Topco Ltd increased its stake in Lexaria Bioscience by 47.8% in the 3rd quarter. XTX Topco Ltd now owns 18,626 shares of the company’s stock valued at $57,000 after buying an additional 6,024 shares during the last quarter. Institutional investors own 13.06% of the company’s stock.

Insider Activity at Lexaria Bioscience

In other news, CEO Richard Christopher acquired 22,828 shares of the stock in a transaction on Monday, December 2nd. The shares were purchased at an average price of $2.24 per share, for a total transaction of $51,134.72. Following the transaction, the chief executive officer now directly owns 22,828 shares of the company’s stock, valued at approximately $51,134.72. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 26.40% of the stock is owned by company insiders.

Lexaria Bioscience Trading Down 5.8 %

Shares of LEXX stock opened at $1.78 on Friday. The company has a fifty day moving average price of $2.10 and a two-hundred day moving average price of $2.66. Lexaria Bioscience Corp. has a one year low of $1.62 and a one year high of $6.85.

Lexaria Bioscience (NASDAQ:LEXX) last posted its quarterly earnings results on Friday, January 10th. The company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.04). Lexaria Bioscience had a negative return on equity of 88.88% and a negative net margin of 1,473.04%. On average, research analysts expect that Lexaria Bioscience Corp. will post -0.59 EPS for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright decreased their price objective on Lexaria Bioscience from $10.00 to $7.00 and set a “buy” rating for the company in a report on Friday, January 24th.

About Lexaria Bioscience

Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods.